This five-day training course gives to professionals a grounding in organizing a drug information system, collecting, analyzing and interpreting drug-related data, and providing information on the drug situation that meets the needs of their different audiences.
The course helps participants to respond to the following questions:
(1) why drug monitoring and data collection is needed and what information is needed for various audiences;
(2) how novel methods and academic research data could be used in the context of monitoring and analyzing the drug situation.
In line with its objectives, the course provides a clear reference framework and explanation of what can and should be done with the data collected and a clear guidance for the implementation of the indicators and other core data.
Scientific advisors:
Alexis Goosdeel, Head, Reitox and international cooperation unit, EMCDDA
Jane Mounteney, PhD, Head of contents, coordination and trend analysis sector, EMCDDA
Tomáš Zábranský, PhD, Reader in Addiction Research, Department of Addictology,1st Faculty of Medicine, Charles University in Prague and General Faculty Hospital in Prague
Lecturers:
Marica Ferri, Head of best practice, knowledge exchange and economic issues sector, Consequences, responses and best practice unit, EMCDDAAlexis Goosdeel, Head, Reitox and international cooperation unit, EMCDDA
Katerina Grohmannova, National Monitoring Centre for Drugs and Drug Addiction
Dirk J. Korf, PhD, University of Amsterdam, Law Faculty, Bonger Institute of Criminology, Netherlands
Jane Mounteney, PhD, Scientific analyst, Policy, evaluation and coordination unit, EMCDDA
Michal Miovský, PhD, Head, Department of Addictology,1st Faculty of Medicine, Charles University in Prague and General Faculty Hospital in Prague
Victor Mravčík, Head, National Focal Point of the Czech Republic
Alessandro Pirona, PhD, Scientific analyst, health and social responses, Interventions, best practice and scientific partners unit, EMCDDA
Istvan Ujvary, hon. associate professor, Budapest University of Technology & Economics; hon. associate professor, University of Szeged, Hungary
Josef Radimecký, PhD, Reader in Drug Policy, Department of Addictology,1st Faculty of Medicine, Charles University in Prague and General Faculty Hospital in Prague
Julian Vicente,Head, Prevalence, consequences and data management unit, EMCDDA
Tomáš Zábranský, PhD, Reader in Addiction Research, Department of Addictology,1st Faculty of Medicine, Charles University in Prague and General Faculty Hospital in Prague